Browsing: GLP1

A once-daily GLP-1 receptor agonist decreased events of level 2 and level 3 hypoglycemia for adults after Roux-en-Y gastric bypass, according to topline results from a phase 3 trial

Nestlé is positioning itself to capitalise on the rapid growth of GLP-1 weight-loss drugs, using artificial intelligence and nutritional science to develop products for the millions of consumers taking medicines such as Ozempic and Wegovy, Reuters has reported

In this photo illustration of a group of weight loss medications on a white background. (Photo by: Michael Siluk/UCG/Universal Images Group

FDA approved the Wegovy pill, the first oral semaglutide for weight management, in late December 2025, and it became available to patients in early January 2026. The response was immediate. Patients who had spent months dreading their weekly injections suddenly had a new question for their doctors, and doctors suddenly had a much harder question…

With the proliferation of GLP 1s globally, anew studypublished in the MJA aims to provide an estimate of the number of adults eligible for TGA approved medicine for chronic weight management

This storywas originally reported by Barbara Rodriguez ofThe 19th.Meet Barbara and read more of their reporting on gender, politics and policy

Almost 8 million Australian adults are currently eligible to use GLP-1 RA medications for chronic weight management, and up to 338 000 adults without diabetes also qualify for treatment for secondary prevention of cardiovascular disease

VCT220 is a novel nonpeptide, orally available glucagon-like peptide-1 receptor agonist (GLP-1RA) designed to reduce the complex administration of injectable GLP-1RAs and the limited bioavailability of on-marketing oral agents for obesity care. We conducted a multicenter, randomized, double-blind, placebo-controlled, phase II trial (Registration no. CTR20233978 and NCT06569355) across 13 sites in China. Adults aged 18–75…

As interest in online GLP-1 weight-management care continues in 2026, this BetterMe Rx review examines the telehealth evaluation process, compounded semaglutide and tirzepatide options, published pricing, provider and pharmacy considerations, and what prospective patients may want to verify before choosing a plan

According to a 2025 poll by KFF (formerly known as the Kaiser Family Foundation), one in eight adults in the U.S. is taking a GLP-1 drug. These medications — the most recognizable are Ozempic® and Wegovy® — were used initially to treat type 2 diabetes, but are now widely used, along with lifestyle and dietary…